-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Evaluate Pharma, a global pharmaceutical market research organization, recently released a report predicting that AbbVie will become the largest drug seller in 2028, with expected sales of $67 billion; Roche followed closely with $65 billion, and Johnson & Johnson ($63 billion) , Merck & Co ($57 billion) and Pfizer ($51 billion) are in the top fi.
Also making the top 10 are Novartis ($52 billion), AstraZeneca ($55 billion), Sanofi ($58 billion), Bristol-Myers Squibb ($43 billion) and GlaxoSmithKline ($440 millio.billion dollar.
AbbVie not afraid of patent cliff
AbbVie's Humira/Humira (adalimumab) has been the world's best-selling drug for years, with annual revenue of about $20 billi.
Next year, Humira will lose patent protection in the.
to biosimilar competiti.
While Humira's super-blockbuster sales will begin to decline due to biosimilar competition, the market for anti-TNF drugs used to treat various inflammatory diseases such as rheumatoid arthritis will remain in place strong dema.
Although industry analysts have been warning in recent years that the company faces a dire fall in revenue as the Humira patent cliff hi.
But so far, Humira has withstood European biosimilar competition, still generating $28 billion in global sales in 2021, and bringing in another $7 billion in the first quarter of this ye.
AbbVie's new autoimmune drugs Skyrizi (risankizumab) and Refu/Rinvoq (upatinib) are seen as successors to Humi.
AbbVie’s financial report for the first quarter of this year showed that both drugs were successful, with Skyrizi’s global sales of $940 million, a year-on-year increase of 67%; Rinvoq’s global sales of $465 million, an increase of 5
AbbVie expects the combination of Skyrizi and Rinvoq to generate a combined $15 billion in revenue for the company in 202
Meanwhile, AbbVie's broad portfolio of other products, such as cancer drug Venclexta (veneclax) and antipsychotic Vraylar (cariprazine hydrochloride), is also accelerating grow.
Venclexta's global sales in 2021 will be $82 billion, an increase of 31% from the previous ye.
Vraylar's sales in 2021 will reach $7 billion, a whopping 82% increase from last ye.
Notably, Vraylar is currently approved to treat bipolar disorder and schizophrenia, and AbbVie hopes to gain approval for other indications such as major depressive disorder in the futu.
AbbVie also has a strong pipeline of migraine products, such as the oral calcitonin gene-related peptide (CGRP) receptor antagonist Qulipta (atogepant) and botulinum tox.
AbbVie is expected to overtake Swiss pharma giant Roche to become the largest pharmaceutical company in 2028, with drug sales reaching about $67 billion over the next six yea.
Big pharma rankings reshuffle
Roche's sales ranking is expected to rise from the current fifth position to second, as its multiple sclerosis drug Ocrevus (ocrelizumab), anti-PD-L1 immunotherapy Tecentriq (atezolizumab) and The hemophilia drug Shuyouli/Hemlibra (emerizumab) is expected to grow strongly over the next six yea.
Although Roche is a large company with a broad pipeline, its 2028 ranking will largely depend on the development of its investigational anti-TIGIT immunotherapy, tiragolumab, which has been hailed as the next generation of immuno-oncology dru.
If tiragolumab is successfully developed, Roche's expected revenue could grow significant.
Sadly, however, tiragolu-mab has recently suffered two phase III clinical trial failures, and now looks ble.
In 2028, Johnson & Johnson is forecast to come in third with $63 billion in sales, followed by Merck with $57 billion and Pfizer in fifth with $51 billion.
It is worth mentioning that due to the good performance of anti-PD-1 immunotherapy Keytruda/Keytruda (pembrolizumab), Merck's ranking will rise from seventh to fourth with sales of $57 billion.
Global sales of Keytruda will reach $39 billion in 2022
Pfizer is leading prescription drug sales in 2021, driven by its Covid-19 vaccine Forbitx/Comirnaty (tozinameran), and is expected to strengthen that position in 202 The company's sales boom during the COVID-19 pandemic won't last long, with Pfizer falling to fifth in sales by 202 However, revenue and rankings can easily change for Pfizer, depending on how Pfizer uses its unexpected means, such as through big acquisitions, to acquire promising biotech asse.
In addition to Pfizer, Novartis and Bristol-Myers Squibb will also drop in the global rankin.
Novartis may rank sixth with $52 billion.
It is predicted that with Bristol-Myers Squibb (BMS) REVLIMID/Revlimid (lenalidomide), ALETO/Eliquis (Apixaban) and Opdivo/Opdivo (nivolumab), e.
The pound drug faces generic competition with expired patents (the three drugs have combined sales of $38 billion in 2021), and BMS will drop to ninth in sales in 2028, with total sales of $43 billion.
BMS is working on a plan to reach $25 billion in new product sales by 2022
AstraZeneca's ranking will rise to 545 in 2028, thanks to sales growth of lung cancer targeted therapy drugs Tagrisso (osimertinib) and PARP inhibitor Lipdrox/Lynparza (olaparib) Billion dollars in annual sales rose to seventh pla.
Sanofi and GlaxoSmithKline will remain at eighth and tenth places, respective.
